Chiltern Announces New Offices and Expansion Plans in Asia Pacific
Chiltern International Limited (Chiltern), a global contract research organization (CRO), has announced its expansion plans in Asia Pacific.
Chiltern has established two new offices and launched operations in Australia and Singapore – with Singapore acting as the hub for its operations in Southeast Asia. This builds upon Chiltern’s operation in India.
Chiltern is also in the process of forming a company and establishing operations in China. Chiltern’s Asia Pacific operations will be led by Umakanta Sahoo, Executive Director, Asia Pacific. Commenting on the growth, “Chiltern’s expansion will provide a platform from which global pharmaceutical and biotech Sponsors can expand their geographic reach and enhance patient recruitment in the Asia Pacific region,” stated Dr. Sahoo.
Glenn Kerkhof, Chiltern CEO, stated, “Asia Pacific is one of the foremost emerging markets in our industry. With the current expansion of pharmaceutical R & D needs into the Asia Pacific region, Chiltern is positioned to meet the needs this growth entails. We are very pleased to provide our clients with access to this market.”
Chiltern is currently recruiting clinical staff and plans to grow its workforce in the Asia Pacific region to 70 by the end of 2010.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
